Oral favipiravir for patients with delayed SARS-CoV-2 viral RNA clearance: a case series

Crit Care. 2020 Sep 25;24(1):578. doi: 10.1186/s13054-020-03288-5.

Dian Fu^{1

2}, Ruiyuan Cao³, Lei Zhao³, Wei Li³, Wu Zhong⁴, Jiqiu Wen^{5

6}

¹ National Clinical and Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, Nanjing, 210002, China.
² Wuhan Huoshenshan Hospital, Wuhan, 430100, China.
³ National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing, 100850, China.
⁴ National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, Beijing, 100850, China. zhongwu@bmi.ac.cn.
⁵ National Clinical and Research Center of Kidney Diseases, Jinling Hospital, Nanjing University School of Medicine, Nanjing, 210002, China. wjqkidney@hotmail.com.
⁶ Wuhan Huoshenshan Hospital, Wuhan, 430100, China. wjqkidney@hotmail.com.

No abstract available

Keywords: COVID-19; Favipiravir; SARS-CoV-2; viral RNA persistence.

Publication types